



ASO VISUAL ABSTRACT


ASO Visual Abstract: Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy

Erin A. Elder, MD¹, Chad A. Livasy, MD², Erin E. Donahue, PhD³, Brittany Neelands, MS^{1,4}, Alicia Patrick, MA^{1,4}, Mckenzie Needham, BS^{1,4}, Terry Sarantou, MD¹, Lejla Hadzikadic-Gusic, MD¹, Arielle L. Heeke, MD⁵, and Richard L. White Jr, MD¹

¹Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; ²Department of Pathology, Levine Cancer Institute, Charlotte, NC; ³Department of Cancer Biostatistics, Levine Cancer Institute, Charlotte, NC; ⁴Clinical Trials Department, Levine Cancer Institute, Charlotte, NC; ⁵Department of Medical Oncology, Levine Cancer Institute, Charlotte, NC

We evaluated the prognostic ability of the residual cancer burden (RCB) class for overall survival (OS), recurrence-free survival (RFS), and distant recurrence-free survival (DRFS) within each phenotypic subset of breast cancer (h

<https://doi.org/10.1245/s10434-022-12300-x>). The RCB had good discriminative ability for OS, RFS, and DRFS, with Harrell's C-indices of 0.68, 0.67, 0.68, respectively.



This work was presented as a webinar and poster at the Society of Surgical Oncology International Conference on Surgical Cancer Care, March 2021.

FUNDING None declared.

DISCLOSURE The authors declare that they have no conflict of interest.

© Society of Surgical Oncology 2022

Published Online: 4 September 2022

R. L. White Jr, MD

e-mail: richard.white@atriumhealth.org

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.